US Stock MarketDetailed Quotes

MRNA Moderna

Watchlist
  • 39.390
  • -0.170-0.43%
Close Dec 20 16:00 ET
  • 39.640
  • +0.250+0.63%
Post 20:01 ET
15.16BMarket Cap-6.78P/E (TTM)

Moderna Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
3.81%1.86B
-30.06%221M
-90.91%167M
-64.22%6.75B
-45.37%2.81B
-44.50%1.79B
-93.08%316M
-69.06%1.84B
6.42%18.88B
-25.90%5.15B
Operating revenue
3.59%1.82B
-37.20%184M
-90.86%167M
-63.81%6.67B
-42.52%2.79B
-43.69%1.76B
-93.53%293M
-69.15%1.83B
4.30%18.44B
-29.46%4.86B
Cost of revenue
-77.06%514M
-84.27%115M
-87.88%96M
-13.35%4.69B
-51.56%929M
103.73%2.24B
-47.07%731M
-22.12%792M
106.95%5.42B
101.47%1.92B
Gross profit
395.37%1.34B
125.54%106M
-93.21%71M
-84.69%2.06B
-41.69%1.88B
-121.42%-454M
-113.03%-415M
-78.75%1.05B
-10.98%13.46B
-46.12%3.23B
Operating expense
-9.44%1.41B
1.17%1.47B
-5.31%1.34B
55.98%6.3B
13.75%1.88B
63.31%1.56B
96.75%1.45B
102.87%1.41B
121.56%4.04B
181.26%1.65B
Selling and administrative expenses
-36.43%281M
-19.28%268M
-10.16%274M
36.84%1.55B
25.33%470M
58.99%442M
57.35%332M
13.81%305M
99.65%1.13B
86.57%375M
Research and development costs
-1.98%1.14B
6.36%1.22B
-6.01%1.06B
47.04%4.85B
16.10%1.41B
41.46%1.16B
61.69%1.15B
104.15%1.13B
65.49%3.3B
86.88%1.21B
Other operating expenses
84.09%-7M
28.57%-20M
----
75.77%-94M
-96.92%2M
69.44%-44M
84.70%-28M
80.95%-24M
47.21%-388M
124.81%65M
Operating profit
96.52%-70M
27.00%-1.36B
-245.90%-1.27B
-145.00%-4.24B
-99.62%6M
-272.56%-2.01B
-176.30%-1.87B
-108.66%-366M
-29.15%9.42B
-70.79%1.58B
Net non-operating interest income expense
2.11%97M
15.38%105M
14.00%114M
123.98%383M
25.97%97M
90.00%95M
160.00%91M
1,011.11%100M
850.00%171M
305.26%77M
Non-operating interest income
-1.90%103M
6.73%111M
10.09%120M
110.50%421M
18.39%103M
81.03%105M
160.00%104M
626.67%109M
1,011.11%200M
1,142.86%87M
Non-operating interest expense
-40.00%6M
-53.85%6M
-33.33%6M
31.03%38M
-40.00%6M
25.00%10M
160.00%13M
50.00%9M
--29M
--10M
Other net income (expense)
85.37%-6M
-177.78%-21M
66.67%-13M
-437.50%-86M
-1,550.00%-33M
-4,200.00%-41M
437.50%27M
-457.14%-39M
44.83%-16M
89.47%-2M
Gain on sale of security
75.68%-9M
-204.55%-23M
57.14%-15M
-260.00%-72M
-1,000.00%-22M
-825.00%-37M
375.00%22M
-483.33%-35M
---20M
---2M
Other non- operating income (expenses)
175.00%3M
-60.00%2M
150.00%2M
-450.00%-14M
---11M
-180.00%-4M
--5M
-300.00%-4M
113.79%4M
--0
Income before tax
101.07%21M
26.87%-1.28B
-281.97%-1.17B
-141.17%-3.94B
-95.77%70M
-260.89%-1.96B
-170.70%-1.75B
-107.21%-305M
-27.93%9.58B
-69.41%1.66B
Income tax
-99.52%8M
0
102.60%10M
-36.36%772M
-177.37%-147M
860.92%1.67B
-233.21%-369M
-167.13%-384M
12.00%1.21B
-64.94%190M
Net income
100.36%13M
7.32%-1.28B
-1,587.34%-1.18B
-156.37%-4.71B
-85.19%217M
-448.03%-3.63B
-162.81%-1.38B
-97.84%79M
-31.47%8.36B
-69.91%1.47B
Net income continuous Operations
100.36%13M
7.32%-1.28B
-1,587.34%-1.18B
-156.37%-4.71B
-85.19%217M
-448.03%-3.63B
-162.81%-1.38B
-97.84%79M
-31.47%8.36B
-69.91%1.47B
Minority interest income
Net income attributable to the parent company
100.36%13M
7.32%-1.28B
-1,587.34%-1.18B
-156.37%-4.71B
-85.19%217M
-448.03%-3.63B
-162.81%-1.38B
-97.84%79M
-31.47%8.36B
-69.91%1.47B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
100.36%13M
7.32%-1.28B
-1,587.34%-1.18B
-156.37%-4.71B
-85.19%217M
-448.03%-3.63B
-162.81%-1.38B
-97.84%79M
-31.47%8.36B
-69.91%1.47B
Basic earnings per share
100.31%0.03
8.01%-3.33
-1,635.00%-3.07
-158.00%-12.33
-85.04%0.57
-456.93%-9.53
-165.23%-3.62
-97.80%0.2
-29.86%21.26
-68.33%3.81
Diluted earnings per share
100.31%0.03
8.01%-3.33
-1,715.79%-3.07
-161.28%-12.33
-84.76%0.55
-476.68%-9.53
-169.08%-3.62
-97.79%0.19
-28.88%20.12
-68.02%3.61
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 3.81%1.86B-30.06%221M-90.91%167M-64.22%6.75B-45.37%2.81B-44.50%1.79B-93.08%316M-69.06%1.84B6.42%18.88B-25.90%5.15B
Operating revenue 3.59%1.82B-37.20%184M-90.86%167M-63.81%6.67B-42.52%2.79B-43.69%1.76B-93.53%293M-69.15%1.83B4.30%18.44B-29.46%4.86B
Cost of revenue -77.06%514M-84.27%115M-87.88%96M-13.35%4.69B-51.56%929M103.73%2.24B-47.07%731M-22.12%792M106.95%5.42B101.47%1.92B
Gross profit 395.37%1.34B125.54%106M-93.21%71M-84.69%2.06B-41.69%1.88B-121.42%-454M-113.03%-415M-78.75%1.05B-10.98%13.46B-46.12%3.23B
Operating expense -9.44%1.41B1.17%1.47B-5.31%1.34B55.98%6.3B13.75%1.88B63.31%1.56B96.75%1.45B102.87%1.41B121.56%4.04B181.26%1.65B
Selling and administrative expenses -36.43%281M-19.28%268M-10.16%274M36.84%1.55B25.33%470M58.99%442M57.35%332M13.81%305M99.65%1.13B86.57%375M
Research and development costs -1.98%1.14B6.36%1.22B-6.01%1.06B47.04%4.85B16.10%1.41B41.46%1.16B61.69%1.15B104.15%1.13B65.49%3.3B86.88%1.21B
Other operating expenses 84.09%-7M28.57%-20M----75.77%-94M-96.92%2M69.44%-44M84.70%-28M80.95%-24M47.21%-388M124.81%65M
Operating profit 96.52%-70M27.00%-1.36B-245.90%-1.27B-145.00%-4.24B-99.62%6M-272.56%-2.01B-176.30%-1.87B-108.66%-366M-29.15%9.42B-70.79%1.58B
Net non-operating interest income expense 2.11%97M15.38%105M14.00%114M123.98%383M25.97%97M90.00%95M160.00%91M1,011.11%100M850.00%171M305.26%77M
Non-operating interest income -1.90%103M6.73%111M10.09%120M110.50%421M18.39%103M81.03%105M160.00%104M626.67%109M1,011.11%200M1,142.86%87M
Non-operating interest expense -40.00%6M-53.85%6M-33.33%6M31.03%38M-40.00%6M25.00%10M160.00%13M50.00%9M--29M--10M
Other net income (expense) 85.37%-6M-177.78%-21M66.67%-13M-437.50%-86M-1,550.00%-33M-4,200.00%-41M437.50%27M-457.14%-39M44.83%-16M89.47%-2M
Gain on sale of security 75.68%-9M-204.55%-23M57.14%-15M-260.00%-72M-1,000.00%-22M-825.00%-37M375.00%22M-483.33%-35M---20M---2M
Other non- operating income (expenses) 175.00%3M-60.00%2M150.00%2M-450.00%-14M---11M-180.00%-4M--5M-300.00%-4M113.79%4M--0
Income before tax 101.07%21M26.87%-1.28B-281.97%-1.17B-141.17%-3.94B-95.77%70M-260.89%-1.96B-170.70%-1.75B-107.21%-305M-27.93%9.58B-69.41%1.66B
Income tax -99.52%8M0102.60%10M-36.36%772M-177.37%-147M860.92%1.67B-233.21%-369M-167.13%-384M12.00%1.21B-64.94%190M
Net income 100.36%13M7.32%-1.28B-1,587.34%-1.18B-156.37%-4.71B-85.19%217M-448.03%-3.63B-162.81%-1.38B-97.84%79M-31.47%8.36B-69.91%1.47B
Net income continuous Operations 100.36%13M7.32%-1.28B-1,587.34%-1.18B-156.37%-4.71B-85.19%217M-448.03%-3.63B-162.81%-1.38B-97.84%79M-31.47%8.36B-69.91%1.47B
Minority interest income
Net income attributable to the parent company 100.36%13M7.32%-1.28B-1,587.34%-1.18B-156.37%-4.71B-85.19%217M-448.03%-3.63B-162.81%-1.38B-97.84%79M-31.47%8.36B-69.91%1.47B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 100.36%13M7.32%-1.28B-1,587.34%-1.18B-156.37%-4.71B-85.19%217M-448.03%-3.63B-162.81%-1.38B-97.84%79M-31.47%8.36B-69.91%1.47B
Basic earnings per share 100.31%0.038.01%-3.33-1,635.00%-3.07-158.00%-12.33-85.04%0.57-456.93%-9.53-165.23%-3.62-97.80%0.2-29.86%21.26-68.33%3.81
Diluted earnings per share 100.31%0.038.01%-3.33-1,715.79%-3.07-161.28%-12.33-84.76%0.55-476.68%-9.53-169.08%-3.62-97.79%0.19-28.88%20.12-68.02%3.61
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.78%